June 2017
Volume 58, Issue 8
Open Access
ARVO Annual Meeting Abstract  |   June 2017
Adipose Stem Cell Therapy for Early Retinal Complications of Diabetes in the Ins2Akita Mouse
Author Affiliations & Notes
  • William Evans
    University of Tennessee Health Science Center, Memphis, Tennessee, United States
  • Ramesh Periasamy
    University of Tennessee Health Science Center, Memphis, Tennessee, United States
  • RAJI RAJESH LENIN
    University of Tennessee Health Science Center, Memphis, Tennessee, United States
  • Rajashekhar Gangaraju
    University of Tennessee Health Science Center, Memphis, Tennessee, United States
  • Footnotes
    Commercial Relationships   William Evans, None; Ramesh Periasamy, None; RAJI RAJESH LENIN, None; Rajashekhar Gangaraju, Cell Care Therapeutics, Inc (P), Cell Care Therapeutics, Inc (I)
  • Footnotes
    Support  NH Grant EY023427 & RPB Grant
Investigative Ophthalmology & Visual Science June 2017, Vol.58, 4033. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      William Evans, Ramesh Periasamy, RAJI RAJESH LENIN, Rajashekhar Gangaraju; Adipose Stem Cell Therapy for Early Retinal Complications of Diabetes in the Ins2Akita Mouse. Invest. Ophthalmol. Vis. Sci. 2017;58(8):4033.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Diabetic retinopathy (DR) is the most common vascular complication in patients with long-standing diabetes, and is the leading cause of blindness in working-age adults. Early stage DR has been shown to involve neurovascular defects, including the breakdown of retinal barrier integrity driven by ischemia, inflammation and apoptosis. In this study, we hypothesized that CD140b enriched adipose stem cells (ASC) or the paracrine factors released by these stem cells could therapeutically rescue early stage DR features.

Methods : Heterozygous male Ins2Akita mice were intravitreally injected with CD140b+ ASC (1000cells/eye), conditioned media (CM, 20x, 1mL/eye) or saline at 24 weeks of age. Age matched C57BL/6J mice with saline injections served as controls. The mice were analyzed after one and 2-weeks post-treatment by Electroretinography, OCT and OKN. The RayBio® Membrane-Based Antibody Array assessed differences in human cytokines released by CD140b+ASC CM compared with CD140b- ASC CM.

Results : Ins2Akita diabetic mice that received saline injection demonstrated significantly decreased b-wave amplitude, decreased visual acuity and increased need for contrast sensitivity compared to non-diabetic mice. On the other hand, diabetic mice that received ASC or CM injection demonstrated robust increase in b-wave amplitude; visual acuity and a decrease need for contrast sensitivity compared to saline treated Ins2Akita diabetic mice (n=7, p<0.05). OCT demonstrated preserved retinal architecture following ASC and CM treatment. Of the 80 proteins tested, 47 proteins remained unchanged (>0.5-<1.5 fold), 9 proteins downregulated (<0.5 fold) and 24 proteins upregulated (>1.5 fold) in CD140b+ASC compared to CD140b-ASC.

Conclusions : First observations of ASC and CM treatment are highly favorable in the treatment against the early retinal complications of diabetes in the Ins2Akita model. Possible beneficial proteins from ASC-CM that are implicated in the observed paracrine effects of ASC in the retina were identified. Future molecular and histological analysis studies are needed to confirm the beneficial effects of the stem cells in vivo. Long term studies will look into identifying complications of stem cell treatment, including potential rejection and need for reinjection.

This is an abstract that was submitted for the 2017 ARVO Annual Meeting, held in Baltimore, MD, May 7-11, 2017.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×